跳至主要内容
临床试验/NCT00077597
NCT00077597已完成3 期

A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease

Hoffmann-La Roche0 个研究点目标入组 182 人开始时间: 2004年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
182
主要终点
Hemoglobin response rate

研究概览

简要总结

This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adult patients >=18 years of age;
  • chronic renal anemia;
  • dialysis therapy for at least 2 weeks before screening.

排除标准

  • women who are pregnant, breastfeeding or using unreliable birth control methods;
  • administration of any investigational drug within 4 weeks before screening.

研究组 & 干预措施

1

Experimental

干预措施: methoxy polyethylene glycol-epoetin beta [Mircera] (Drug)

2

Active Comparator

干预措施: epoetin (Drug)

结局指标

主要结局

Hemoglobin response rate

时间窗: Weeks 1-24

次要结局

  • Hb over time, time to target Hb response, incidence of RBC transfusions. Vital signs, ECG, AEs, laboratory values\n(Throughout study)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验